Cancer Clinical Trial
Official title:
A Pilot, Randomized, Self-controlled Study of the Effects of Intratympanic Sodium Thiosulfate on the Degree of Hearing Loss in Patients Receiving Cisplatin Therapy
This is a pilot, randomized, self-controlled study of the effects of intratympanic sodium
thiosulfate (STS) on the degree of hearing loss in patients receiving cisplatin therapy.
Sodium thiosulfate is an inactive ingredient contained in sulfacetamide ophthalmic solution
which is used routinely as an otic solution delivered to the middle ear space.
The hypothesis of this study is that local administration of sodium thiosulfate (STS) will
result in improved hearing compared to ears not receiving the study drug in patients
receiving systemic cisplatin therapy.
Platinum-based chemotherapeutic agents are used to treat a number of malignant tumors, both
in children and adults. Examples of such tumors include: osteosarcoma, Wilms' tumor,
rhabdomyosarcoma, neuroblastoma, Ewing's sarcoma, primary brain tumors, carcinoma, and
various other solid tumors. Cisplatin is associated with a dose-dependent, high frequency
sensorineural hearing loss. With increasing doses, the hearing loss worsens to include the
speech frequencies. Vestibular function can also be damaged by platinum-based toxicity.
Cisplatin causes ototoxicity through the formation of reactive oxygen species and activation
of the apoptotic pathway in outer hair cells and the stria vascularis.
Rates of ototoxicity are approximately 80% with audiologic findings of hearing loss, and 20%
with symptomatic hearing loss. These numbers are higher for those receiving high dose
cisplatin, children, those with prior irradiation and those with prior hearing loss.
A number of agents have been investigated in animal models as otoprotection against the toxic
effects of cis- and carboplatin. Among these, sodium thiosulfate (STS) has shown particular
promise as an otoprotective agent. STS is approved by the US Food and Drug Administration
(FDA) as an antidote for cyanide and nitroprusside toxicity and for calciphylaxis. STS has
been shown to act as both an antioxidant as well as a chelating agent in vivo. The chelating
properties of the sulfur-thiol functional group are believed to be responsible for the
otoprotective effects of STS, binding to, and inactivating the platinum. The thiol compound
may also act to scavenge reactive oxygen species produced by the platinum, thus preventing
the initiation of the apoptotic pathway.
Several studies have demonstrated the otoprotective effects of intravenous STS in animal
models. Subsequent studies have shown similar benefit when STS is administered intravenously
to humans. A major drawback to this mode of delivery, however, is the fear that it reduces
the anti-tumor activity of the platinum. Sodium thiosulfate is believed to bind to cisplatin,
forming a complex that is then excreted by the kidneys. Though this may decrease the
ototoxicity associated with the platinum, it may also decrease the anti-neoplastic properties
of the agent. There are conflicting reports of reduced tumoricidal properties of STS in
vitro, though there are no in vivo studies suggesting this adverse effect in vivo.
In view of the potential for systemic STS to reduce the tumoricidal effects of platinum
agents, researchers have sought an alternate mode of delivery. Recent animal studies have
examined the effect of sodium thiosulfate delivered locally to the middle ear space. Stocks,
et al demonstrated an otoprotective effect of STS delivered to the middle ear space of guinea
pigs. Wang, et al showed complete prevention of the ototoxic effects of cisplatin in guinea
pigs treated with round window application of STS. In their study, both the compound action
potential (CAP) and distortion product otoacoustic emissions (DPOAE) were unchanged, and both
outer hair cells (OHC) and inner hair cells (IHC) were preserved. This effect, however, was
not demonstrated in a similar study by Wimmer, et al. The temporal and spatial separation of
the platinum and STS in these animal studies prompted Zuur and colleagues to state that, "in
the future, it may be desirable to examine additional possibilities for two-route
administration schemes for chemotherapy and otoprotective drugs in humans." There are no
studies to date of intratympanic sodium thiosulfate in humans.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|